CSL in Talks With Vifor Pharma Over Potential Transaction
December 12 2021 - 7:49PM
Dow Jones News
By Stuart Condie
SYDNEY--Australian biopharmaceutical company CSL Ltd. said it is
in talks with Vifor Pharma Ltd. over a potential acquisition of the
Switzerland-based pharmaceutical company.
CSL said Monday that there was no certainty of a transaction, or
indication of when any transaction would occur. It said it didn't
intend to comment further outside of its continuous disclosure
obligations.
Vaccine and blood-products maker CSL, the second-largest
ASX-listed firm by market capitalization, initially acknowledged
Australian media reports on the discussions last week, without
confirming their existence.
Investment bank Citi said last week that any move for Vifor
would likely be EPS accretive, given CSL trades at a significantly
higher multiple than Vifor, which develops, manufactures and
markets iron-deficiency products.
Vifor has a market capitalization of 7.69 billion Swiss francs
(US$8.35 billion). CSL's market capitalization is A$136 billion
(US$97.5 billion).
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
December 12, 2021 19:34 ET (00:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
CSL (ASX:CSL)
Historical Stock Chart
From Nov 2024 to Dec 2024
CSL (ASX:CSL)
Historical Stock Chart
From Dec 2023 to Dec 2024
